News | April 12, 2022
Wacker, CordenPharma to produce mRNA vaccines for Germany
Both companies have been selected for stand-by production by German government
Both companies have been selected for stand-by production by German government
CanSinoBIO will continue to focus on developing a variety of innovative preventive vaccines in its diversified product pipeline with proprietary technologies, including the inhaled version of its COVID-19 vaccine, Convidecia
Primarily set up to address the Covid-19 emergency, the WHO technology transfer hub has the potential to expand manufacturing capacity for other products as well, including treatments, and target other priorities such as malaria, HIV and cancer
mRNA-based therapies involve the administration of mRNA in patients so that patients' own cells can produce the encoded therapeutic antibody
The open-label, multicenter, randomized Phase 1 trial is designed to evaluate the safety and immunogenicity of experimental HIV trimer mRNA vaccines
The company is investing up to US $ 500 million to produce up to 500 million doses each year for the African continent
The 15-year agreement will leverage dedicated commercial fill-finish manufacturing capacity in the US for mRNA vaccines and therapies
These programs are: Herpes simplex virus (HSV) vaccine candidate, Varicella-zoster virus (VZV) vaccine candidate and Checkpoint cancer vaccine.
It is being developed by Pune-based Gennova Biopharmaceuticals
DS-5670 is an mRNA vaccine against Covid-19 using a novel nucleic acid delivery technology discovered by the company
Subscribe To Our Newsletter & Stay Updated
